Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
For full access to this article login to GEN Select now.
Road to Antibiotic Approval Made Clearer
Regulatory Hurdles Are Higher, but a New Well-Defined Path Means We Know How High to Jump
- Antibiotic development has become a challenging therapeutic area. Shifting and evolving regulatory guidelines have made design of clinical trials difficult and the prospect for marketing approval fairly low. In addition, the short-term treatment regimens have made the sector relatively unattractive from a return on investment perspective, particularly for antibiotics ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.